Directed Genomics, New England Biolabs to develop new technologies for NGS

New England Biolabs (NEB®) and Directed Genomics together announce that they have established a partnership to develop a suite of new technologies for next generation sequencing (NGS), including target enrichment.

Commenting on the announcement, James V. Ellard, CEO of NEB said, "Directed Genomics is an innovative technology development organization building simple, efficient genomic workflows. Their unique, enzyme-based technologies offer substantial improvements in performance, efficiency and speed for NGS sample preparation.

"We are a nimble, entrepreneurial, technology development company purpose-built to move ideas quickly from initial concept to market," says Cynthia Richard, Founder and President of Directed Genomics. "Partnering with NEB allows us to leverage an extensive knowledge-base of enzyme activities, best-in-class manufacturing practices and their global commercial footprint."

The first joint product concept to be developed as a result of this partnership, which is being presented at the American Society of Human Genetics (ASHG) annual conference in San Diego, California, October 18-22nd, is a target enrichment technology that combines enrichment with NGS library construction into a single, seamless protocol. The approach is scalable and enables the conversion of small amounts of genomic DNA into sequence-ready libraries, in about six hours. Enrichment is also highly specific, enabling greater coverage of target regions with fewer sequencing reads than other currently-available target-capture methods.

"Though still in development, the technical data produced to date is impressive. We look forward to further developing this method and applying it in a variety of research and translational workflows," commented Theodore Davis, Director of Applications and Product Development at NEB.

 

Source:

New England Biolabs

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    New England Biolabs. (2019, June 20). Directed Genomics, New England Biolabs to develop new technologies for NGS. News-Medical. Retrieved on August 14, 2022 from https://www.news-medical.net/news/20141020/Directed-Genomics-New-England-Biolabs-to-develop-new-technologies-for-NGS.aspx.

  • MLA

    New England Biolabs. "Directed Genomics, New England Biolabs to develop new technologies for NGS". News-Medical. 14 August 2022. <https://www.news-medical.net/news/20141020/Directed-Genomics-New-England-Biolabs-to-develop-new-technologies-for-NGS.aspx>.

  • Chicago

    New England Biolabs. "Directed Genomics, New England Biolabs to develop new technologies for NGS". News-Medical. https://www.news-medical.net/news/20141020/Directed-Genomics-New-England-Biolabs-to-develop-new-technologies-for-NGS.aspx. (accessed August 14, 2022).

  • Harvard

    New England Biolabs. 2019. Directed Genomics, New England Biolabs to develop new technologies for NGS. News-Medical, viewed 14 August 2022, https://www.news-medical.net/news/20141020/Directed-Genomics-New-England-Biolabs-to-develop-new-technologies-for-NGS.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
ERS Genomics and New England Biolabs sign agreement to commercialize CRISPR/Cas9 tools, reagents